RNS Number : 8650N
Roquefort Therapeutics PLC
07 June 2022

7 June 2022


Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")


Notice of Annual General Meeting


Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, has today posted its Notice of Annual General Meeting to Shareholders. The Annual General Meeting is scheduled to take place at the offices of Ince Gordon Dadds LLP, Aldgate Tower, 2 Leman Street, London E1 8QN at 10.00 am on 30 June 2022.


The Notice of Annual General Meeting and Forms of Proxy can be downloaded from the Company's corporate website at https://www.roquefortplc.com/category/shareholder-documents/





Roquefort Therapeutics plc

Stephen West (Chairman)

+44 (0)20 3290 9339


Buchanan (Public Relations)

Ben Romney / Jamie Hooper / George Beale


Optiva Securities Limited (Broker)


+44 (0)20 7466 5000

Christian Dennis

+44 (0)20 3411 1881


For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on Twitter.


LEI: ‎254900P4SISIWOR9RH34


About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company developing products through the pre-clinical phase prior to partnering or selling to big pharma.  The Company is a pre-clinical biotech company focused on developing first in class Midkine targeting drugs for the treatment of cancer.


Through extensive research resulting in validation through publication in over 1,000 scientific journals, Roquefort Therapeutics has identified the potential to exploit the broad therapeutic potential of Midkine for a number of clinical indications of unmet needs. Roquefort Therapeutics holds an exclusive licence to the largest global IP portfolio on Midkine. The Midkine blocking drug development markets have significant global market potential (in the multi-billion dollars). Roquefort Therapeutic's pre-clinical program is currently underway with an initial focus on cancer.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.